Previous 10 | Next 10 |
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announce...
CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today...
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare disea...
2023-04-19 07:51:25 ET Summary The extent to which FIRDAPSE in the treatment of LEMS can support ongoing growth is a big question mark for Catalyst shareholders. The FYCOMPA acquisition comes with more big question marks. Although enjoying comfortable liquidity, Catalyst will ...
2023-04-18 12:00:51 ET Summary Catalyst Pharmaceuticals, Inc. filed a lawsuit against Teva Pharmaceutical Industries Limited's ANDA. At the heart of the situation is a patent that should never have been granted. While courts have not addressed this, instead focusing on orphan ...
2023-04-17 15:42:50 ET Summary Catalyst Pharmaceuticals, Inc. appears to be set up nicely for earnings and revenue growth with a possible expansion of its valuation ratios. Downside appears to be limited, as Catalyst Pharmaceuticals is currently valued in line with its profitable ...
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.49% on the day to $17.69. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people w...
2023-04-04 10:23:00 ET While there's no telling precisely when a new bull market is going to roll around, it will because eventually one always does. That means now's the time to identify shares of businesses that are positioned to soar once sentiment improves. Biotech Catalyst Pharma...
2023-03-31 06:00:00 ET Summary Defense is sometimes the best offense. In the spirit of March Madness and market volatility, it’s time to get defensive as the banking crisis and market uncertainty fuel U.S. recession risks. As stocks fluctuate and the Fed suggests tighter cr...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...
2024-06-03 10:15:02 ET Oppenheimer analyst issues BUY recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Buy. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...